BLLNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BillionToOne, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$101.03+2.91 (+2.97%)
Close on Oct 19, 2026
- Market cap
- $5.50B
- P/E (TTM)
- 721.6
- Dividend yield
- –
BillionToOne, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Prenatal | $277.11M | $145.90M | $68.80M | 90.8% | +89.9% |
| Oncology | $24.95M | $2.94M | $0 | 8.2% | +747.6% |
| Clinical trial support and other services | $3.05M | $3.74M | $2.93M | 1.0% | -18.3% |
By region
From the segment and revenue-disaggregation notes of BillionToOne's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.